{"prompt": "['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 30 of 122', 'Questionnaires are to be completed in the order given in Table 1. Not all questionnaires are', 'completed at the same visits; questionnaires are to be completed at the study visits indicated', 'in Appendix 4, Appendix 5, and Appendix 6.', 'The same parent/caregiver should complete all relevant questionnaires during the study. For', 'age-relevant questionnaires, a subject who transitions from one age group to the next age', 'group during the study will complete the version first used. All subject and parent/caregiver', 'questionnaires will be administered before any clinical or physical assessments or dose of', 'AR101, except as follows:', 'Bespoke questions on assessment of food challenge outcomes will be administered', 'after the food challenge is completed and the results are explained.', 'The European Quality of Life 5-Dimensions health questionnaire (EQ-5D) will also', 'be administered when a severe allergic reaction due to study product or food allergen', 'exposure occurs during an up-dosing visit or at home and 1 week later.', 'Table 1: Order of Subject and Parent/Caregiver Questionnaires To Be Completed', 'Parent/Caregiver', 'Subject Aged 8 to 12 Years', 'Subject Aged 13 to 17 Years', '1', 'EQ-5D-5L', 'EQ-5D-Y', 'EQ-5D-5L', '2', 'FAQL-PB', 'FAQLQ-CF, FAIM-CF', 'FAQLQ-TF, FAIM-TF', '3', 'HADS', 'Bespoke questions on global', 'Bespoke questions on global', 'assessment of HRQOL (child', 'assessment of HRQOL', 'form)', '(teenager form)', '4', 'EQ-5D-Y proxy (for subject', 'Bespoke questions on control of', 'aged 4-7 years)', 'peanut allergy and confidence in', 'managing allergic reactions', '(teenager form)', '5', 'FAQLQ-PF, FAIM-PF (for', 'Bespoke questions on', 'subject aged 12 years);', 'assessment of food challenge', 'FAQLQ-PFT, FAIM-PFT (for', 'outcomes (patient form) [1]', 'subject aged 13-17 years)', '6', 'Bespoke questions on global', 'TSQM-9 (for AR101-treated', 'assessment of HRQOL', 'subject at early', '(parent/caregiver form)', 'discontinuation/study exit)', '7', 'Bespoke questions on control of', 'Bespoke exit questionnaire', 'peanut allergy and confidence in', '(patient form, for AR101-treated', 'managing allergic reactions', 'subject at early', '(parent/caregiver form)', 'discontinuation/study exit)', '8', 'Bespoke questions on', 'Qualitative exit interview (for', 'assessment of food challenge', 'AR101-treated subject at early', 'outcomes (parent/caregiver', 'discontinuation/study exit) [2]', 'form) [1]', '9', 'TSQM-9 (for AR101-treated', 'subject aged 4-12 years at early', 'discontinuation/study exit)', '10', 'Bespoke exit questionnaire', '(parent/caregiver form, for']['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 31 of 122', 'Parent/Caregiver', 'Subject Aged 8 to 12 Years', 'Subject Aged 13 to 17 Years', 'AR101-treated subject at early', 'discontinuation/study exit)', '11', 'Qualitative exit interview (for', 'AR101-treated subject at early', 'discontinuation/study exit) [2]', 'Questionnaires are to be completed at the study visits indicated in Appendix 4, Appendix 5, and Appendix 6.', '[1] To be completed after the end of the observation period for the food challenge (OLFC or optional', 'RWPC) and after the results are explained.', '[2]', 'To be conducted in a random sample of parents/caregivers and subjects aged > 13 years at study exit or', 'early discontinuation.', 'EQ-5D-5L, European Quality of Life 5-Dimensions 5-Levels health questionnaire; EQ-5D-Y, EQ-5D Youth;', 'FAIM, Food Allergy Independent Measure; FAIM-CF, FAIM - child form; FAIM-PF, FAIM - parent form;', 'FAIM-PFT, FAIM - parent form teenager; FAIM-TF, FAIM - teenager form; FAQL-PB, Food Allergy', 'Quality of Life - Parental Burden; FAQLQ, Food Allergy Quality of Life Questionnaire; FAQLQ-CF,', 'FAQLQ - child form; FAQLQ-PF, FAQLQ - parent form; FAQLQ-PFT, FAQLQ - parent form teenager;', 'FAQLQ-TF, FAQLQ - teenager form; HADS, Hospital Anxiety and Depression Scale;', 'HRQOL, health-related quality of life; OLFC, open-label food challenge; RWPC, real-world peanut', 'challenge; TSQM-9, Treatment Satisfaction Questionnaire for Medication.', '5.2.4', 'General Procedures for Subjects Receiving AR101 Treatment', 'Before administration of the first and any subsequent dose of AR101 at the study site, the', \"subject's health status must be at baseline state, including no presence of active wheezing,\", 'flare of atopic disease (eg, atopic dermatitis), or suspected intercurrent illness. The subject', 'must have fully recovered from any previous illness for at least 3 days, depending on the', 'severity of the illness per investigator assessment.', 'A study physician must always be readily available during dosing at the study site. At', 'minimum, subjects will be evaluated for signs and symptoms of an allergic reaction at 15 to', '30 minutes postdose and every 30 minutes thereafter (with vital signs measurements of blood', 'pressure and heart rate), until at least 90 minutes postdose or the end of the observation', 'period, whichever is last. The postdose observation period may be shortened to 30 minutes', 'during maintenance if no allergy symptoms occurred during the previous 3 maintenance', 'visits.', 'Allergy symptoms will be assessed as follows:', 'Symptoms of allergic reactions will be evaluated per Section 8.5.1.', 'The tolerability of study product will be evaluated per Section 8.5.1.2.', 'The treatment of allergic reactions and dose adjustment of study product will follow', 'guidelines per Sections 8.5.2 and 8.5.3.']\n\n###\n\n", "completion": "END"}